{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:10:13Z","timestamp":1759050613045,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jneuroim.2022.577877","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:24:31Z","timestamp":1650594271000},"page":"577877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Changes in ganglioside antibody positivity rates during the COVID-19 pandemic"],"prefix":"10.1016","volume":"367","author":[{"given":"Michael K.","family":"Racke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin K.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond A.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey W.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.577877_bb0005","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-020-10124-x","article-title":"Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases","volume":"268","author":"Abu-Rumeileh","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barre variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0015","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1212\/CPJ.0000000000000880","article-title":"A case series of Guillain-Barr\u00e9 Syndrome After COVID-19 infection in New York","volume":"11","author":"Chan","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/jnnp-2020-324279","article-title":"Antiganglioside antibodies in Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2 infection","volume":"91","author":"Civardi","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2022.577877_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41423-020-0388-9","article-title":"Physiology of gangliosides and the role of antiganglioside antibodies in human diseases","volume":"17","author":"Cutillo","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0030","article-title":"GM1 ganglioside antibody and COVID-19 related Guillain Barre syndrome - a case report, systemic review and implication for vaccine development","volume":"12","author":"Dufour","year":"2021","journal-title":"Brain Behav. Immun. Health."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2022.577877_bb0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jns.2014.07.040","article-title":"Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies","volume":"345","author":"Elf","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp-2020-324837","article-title":"Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions","volume":"92","author":"Filosto","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2022.577877_bb0045","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ana.25987","article-title":"Incidence, clinical, risk factors and outcomes of Guillain-Barre in COVID-19","volume":"89","author":"Fragiel","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00415-020-09911-3","article-title":"Guillain-Barr\u00e9 syndrome in the COVID-19 era: just an occasional cluster?","volume":"268","author":"Gigli","year":"2021","journal-title":"J. Neurol."},{"issue":"268","key":"10.1016\/j.jneuroim.2022.577877_bb0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00415-020-10108-x","article-title":"Immune-mediated neurological syndromes in SARS-CoV-2-infected patients","volume":"2021","author":"Guilmot","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0060","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000009619","article-title":"Miller fisher syndrome and polyneuritis cranialis in COVID-19","volume":"95","author":"Guti\u00e9rrez-Ortiz","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/cen3.12644","article-title":"Emerging infectious diseases, vaccines and Guillain-Barr\u00e9 syndrome","author":"Koike","year":"2021","journal-title":"Clin. Exp. Neuroimmunol.."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0075","first-page":"352","article-title":"A case report of acute motor and sensory polyneuropathy as the presenting symptom of SARS-CoV-2","volume":"4","author":"Kopscik","year":"2020","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0080","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3174\/ajnr.A6609","article-title":"COVID-19-associated miller fisher syndrome: MRI findings","volume":"41","author":"Lantos","year":"2020","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2478\/jccm-2020-0038","article-title":"Atypical variant of Guillain Barre syndrome in a patient with COVID-19","volume":"6","author":"Lowery","year":"2020","journal-title":"J. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barre syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0095","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00415-020-10219-5","article-title":"A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection","volume":"268","author":"Masuccio","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/CND.0000000000000322","article-title":"Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview","volume":"22","author":"Petrelli","year":"2020","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0105","article-title":"Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia","volume":"4","author":"Rogawski","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jneuroim.2022.577877_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sevjar","year":"2011","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurrent Guillain-Barr\u00e9 syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0120","doi-asserted-by":"crossref","first-page":"633.e1","DOI":"10.1016\/j.cmi.2020.11.013","article-title":"Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with high incidence of COVID-19 cases: a population-based study","volume":"27","author":"Stefanelli","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jneuroim.2022.577877_bb0125","article-title":"Antiganglioside antibodies in neurological diseases","volume":"408","author":"Wanleenuwat","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577877_bb0130","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/jnnp-2014-309056","article-title":"Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis, and Oxfordshire cohort study","volume":"86","author":"Webb","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:42:07Z","timestamp":1759048927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S0165572822000728"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577877","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in ganglioside antibody positivity rates during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577877"}}